Brief: Sanofi And Regeneron's Dupixent Approved To Treat Bullous PEMPHIGOID In Japan
24/03/2026 06:07
March 24 (Reuters) - Sanofi SA SASY.PA: SANOFI AND REGENERON'S DUPIXENT APPROVED IN JAPAN AS FIRST TARGETED MEDICINE TO TREAT ADULTS WITH BULLOUS PEMPHIGOID- DUPIXENT APPROVED IN JAPAN IN CERTAIN PATIENTS WITH ATOPIC DERMATITIS, ASTHMA, CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS, PRURIGO NODULARIS, CHRONIC SPONTANEOUS URTICARIA, AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE GRANTED MARKETING AND MANUFACTURING AUTHORIZATION FOR DUPIXENT (DUPILUMAB) FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE BULLOUS PEMPHIGOID Source text: ID:nGNE2nKPq2 Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes